High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

Haematologica

Volumn 95, Issue 7, 2010, Pages 1191-1197

  Greiner, Jochen ^a   Schmitt, Anita ^b   Giannopoulos, Krzysztof ^a   Rojewski, Markus T ^a   Götz, Marlies ^a   Funk, Isabel ^a   Ringhoffer, Mark ^a   Bunjes, Donald ^a   Hofmann, Susanne ^a   Ritter, Gerd ^c   Döhner, Hartmut ^a   Schmitt, Michael ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Acute myeloid leukemia; Cancer vaccines; Epitope peptides; Leukemia associated antigens; Receptor for hyaluronic acid mediated motility; RHAMM CD168

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CCR7; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MESSENGER RNA; PEPTIDE VACCINE; RECEPTOR FOR HYALURONIC ACID MEDIATED MOTILITY PROTEIN; RECEPTOR FOR HYALURONIC ACID MEDIATED MOTILITY R3 PEPTIDE VACCINE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; CANCER VACCINE; HERMES ANTIGEN; HYALURONAN-MEDIATED MOTILITY RECEPTOR; PEPTIDE FRAGMENT; SCLEROPROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG FEVER; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEASIBILITY STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; LYMPHOCYTE COUNT; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; IMMUNITY; IMMUNOLOGY; MIDDLE AGED; T LYMPHOCYTE; VACCINATION;

AGED; ANTIGENS, CD44; CANCER VACCINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNITY; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; VACCINATION;

EID: 77952952932     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.014704     Document Type: Article

References (24)

1. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, et al. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood. 2006;108(13):4109-17.
2. Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P, et al. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood. 2005;106(3):938-45.
3. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer. 2004;108(5):704-11.
4. Greiner J, Bullinger L, Guinn BA, Dohner H, Schmitt M. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res. 2008;14(22):7161-6.
5. Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008; 111(3):1357-65.
6. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111 (1):236-42.
7. 1 tumor gene)-spedfic cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004;101(38):13885-90.
8. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krahn G, et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol. 2002;30(9):1029-35.
9. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia-definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica. 2006;91(12):1653-61.
10. Giannopoulos K, Mertens D, Buehler A, Barth TFE, Idler I, Möller P, et al. The candidate immunotherapeutical target receptor for hyaluronic acid mediated motility (RHAMM) is associated with proliferation and shows prognostic value inB-cell chronic lymphocytic leukemia. Leukemia. 2009 (23): 519-27.
11. Long MC, Bidanset DJ, Williams SL, Kushner NL, Kern ER. Determination of antiviral efficacy against lymphotropic herpesviruses utilizing flow cytometry. Antiviral Res. 2003;58(2):149-57.
12. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361(9356):489-91.
13. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302.
14. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-9.
15. Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother. 2008;57(3):289-302.
16. Parmiani G, Pilla L, Castelli C, Rivoltini L. Vaccination of patients with solid tumours. Ann Oncol. 2003;14(6):817-24.
17. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004;18(1):165-6.
18. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113(26):6541-8.
19. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005,115(3):739-46.
20. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-87.
21. Pacholczyk R, Kem J, Singh N, Iwashima M, Kraj P, Ignatowicz L. Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells. Immunity. 2007;27(3):493-504.
22. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program. 2003: 331-49.
23. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999;59(13):3128-33.
24. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-60.